Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Spruce BiosciencesSPRB +7.30%42 3-Year EPS without NRI Growth Rate is 32.00% as of Jun. 2026, which is 196% above its 10-year median of 10.80. GuruFocus rates SPRB with a GF Score™ of 42/100 and a GF Value™ of $4.08 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 1,160 Biotechnology companies, Spruce Biosciences ranks better than 69.05% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 32.00% per year.
During the past 5 years, the average EPS without NRI Growth Rate was 28.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 8 years, the highest 3-Year average EPS without NRI Growth Rate of Spruce Biosciences was 36.90% per year. The lowest was -11.00% per year. And the median was 10.80% per year.
Spruce Biosciences (NAS:SPRB) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Spruce Biosciences 3-Year EPS without NRI Growth Rate Related Terms
SPRB vs CDXS, CRBU, MENS: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Spruce Biosciences's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Spruce Biosciences 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Spruce Biosciences's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Spruce Biosciences's 3-Year EPS without NRI Growth Rate falls into.
Spruce Biosciences 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 32.00% mean?
Spruce Biosciences (SPRB) has a 3-Year EPS without NRI Growth Rate of 32.00% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Spruce Biosciences and its competitors. This is 196% above median its historical median of 10.80. According to the industry distribution chart, Spruce Biosciences ranks #359 out of 1160 companies in the Biotechnology industry, placing it in the top 30.9%.
Is Spruce Biosciences' 3-Year EPS without NRI Growth Rate too high?
Spruce Biosciences' current 3-Year EPS without NRI Growth Rate of 32.00% is 196% above median its 10-year median of 10.80. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.05. Spruce Biosciences' value of 32.00% is 99.4% above this industry median. Based on the distribution chart, Spruce Biosciences ranks #359 out of 1160 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Spruce Biosciences has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Spruce Biosciences' 3-Year EPS without NRI Growth Rate compare to CDXS and CRBU?
According to the Biotechnology industry distribution chart, Spruce Biosciences ranks #359 out of 1160 companies for 3-Year EPS without NRI Growth Rate. This puts Spruce Biosciences in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 16.05. Spruce Biosciences' value of 32.00% is 99.4% above this benchmark. While the company's 10-year median is 10.80 vs. the industry median of 16.05, Spruce Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.05, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Spruce Biosciences's current 3-Year EPS without NRI Growth Rate of 32.00% is 99.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Spruce Biosciences and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.05 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Spruce Biosciences's current 3-Year EPS without NRI Growth Rate is 32.00%, which is 196% above median its own 10-year median of 10.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spruce Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Spruce Biosciences (SPRB) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.08, compared to a current price of $59.70 — trading 1363.2% above its estimated fair value. The current 3-Year EPS without NRI Growth Rate is 32.00%, which is 196% above median its 10-year median of 10.80 and 99.4% above the Biotechnology industry median of 16.05. Spruce Biosciences' overall GF Score™ is 42/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Spruce Biosciences (SPRB), the current 3-Year EPS without NRI Growth Rate is 32.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Spruce Biosciences (SPRB) Overvalued in 2026?
Based on GuruFocus' analysis, Spruce Biosciences stock appears to be overvalued.
The current stock price of $59.70 is trading 1363.2% above its estimated GF Value™ of $4.08.
GuruFocus considers Spruce Biosciences to be Significantly Overvalued.
Key valuation signals for SPRB:
3-Year EPS without NRI Growth Rate: 32.00% (196% above median its 10-year median of 10.80)
GF Value™: $4.08 vs. price of $59.70 (1363.2% above fair value)
Industry Position: 99.4% above the Biotechnology median (#359 of 1160)
No single metric tells the full story. See the SPRB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.
42GF Score
Get the complete analysis for SPRB
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPRB has been successfully added to your 
